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INTRODUCTION
The distribution of orexin peptides and their receptors in the brain suggests that they may play a key role in multiple regulatory systems, including feeding, autonomic control, sleep, memory, and the reward system (for recent review see 1 ). Experiments revealed that orexin levels in the lateral hypothalamic area of rats gradually increased during the active period and exponentially declined in the rest phase 2 . The levels of orexin A in the cerebrospinal fluid 3 or plasma 4 of narcoleptic patients is abnormally decreased (reduction 80 to 100%). Additionally, a correlation between orexin A levels and individuals with post traumatic stress disorder (PTSD) was made where the level was noticeably decreased 5 . There is a considerable amount of evidence suggesting a regulatory role of orexin peptides in cognition performance impaired by sleep deprivation.
It was found that intranasal application of orexin A reduces the effect of sleep deprivation on the cognitive performance in non-human primates 6 . On the other hand, the administration of an orexin-1 receptor antagonist decreased the attentional performance in rats 7 , suggesting that orexins contribute to the attention. Therefore, it is hypothesized that measuring the level of orexin A in blood of human subjects can allow us to predict a vigilance state and cognitive performance. Orexin A and B are both produced from a common precursor polypeptide by proteolytic cleavage. The sequences of orexin A are completely conserved among several mammalian species while orexin B is highly conserved (93%) with two residues substituted in rat and mouse comparing with the human sequence 8 . Human orexin A neuropeptide has 33 amino acids and contains two disulfide bonds in N-terminal region. The concentration of orexin A in tissue and blood is much higher than the concentration of orexin B, where orexin A can be found at pg/mL levels, and orexin B is undetectable 9 . Furthermore, orexin A is highly lipophilic and can rapidly cross the blood-brain barrier 10 . In contrast, orexin B has low lipophilicity and is rapidly metabolized in blood which makes it difficult to detect. Orexin neuropeptides act via two G protein-coupled cell surface receptors named orexin receptor-1 (Ox1R) and orexin receptor two (Ox2R). The activation of Ox1R by orexin A is 10 to 100 times higher than that of orexin B, whereas the activity at the Ox2R is in the same range for both peptides 11 . 16 , have recently been studied for detecting a variety of molecules 17, 18 . These sensors can be easily integrated into a modular chip design and programmed to sense a specific molecular target by functionalizing the semiconductor with a biorecognition element (BRE). The BRE is typically an antibody 19 , DNA or RNA aptamer 20 , or peptide 21 specifically selected and designed to bind the target of interest. The binding event changes the local electron density on the surface of the semiconductor resulting in a change in the current flowing through the device, signaling the presence of the target. In this work, we present a real-time electronic based sensor platform for detecting orexin A in biofluids at physiologically relevant concentrations.
RESULTS
We have developed an electronic based (FET) label-free biosensor with a novel integrated biological recognition element that provides real-time detection of orexin A in saliva and serum. The biological recognition element which binds orexin A was selected using a phage display technique, detailed in the methods section, and verified through both binding kinetics and computational modeling. The BRE is integrated into an electronic based sensor platform where the target binding event is reported discretely and rapidly ( Supplementary Fig. 1 ). (Fig. 1) indicates that OAPB1 binds with higher affinity than OABP2 ( Table 1) . From these rate constants, Kd is calculated as 74 +/-2.1 nM for OABP1, which is comparable to the affinities determined from ELISA. As a negative control, the OABP1 sequence was randomized to QRQLNDKLSIISGSG
(termed NCP) and tested for binding to orexin A, showing no binding (Fig. 1) . OABP1
was tested for its ability to bind native protein in solution and used in a peptide pull down experiment in which it was bound to streptavidin magnetic beads and incubated overnight with 50 µM solutions of orexin A. The beads were washed extensively and the bound protein was eluted. Samples were run on a SDS-PAGE gel and detected by Western Blot with an anti-orexin A monoclonal antibody (Supplementary Fig. 2 ). Elution samples were split with half of the sample analyzed by silver stain and half analyzed by Western Blot. From the silver stained gel, it can be seen orexin A was precipitated along with one other prominent proteins from the sample. As a preliminary test of specificity in complex biological matrices, 200 ng to 1665 ng of orexin A was spiked into human brain cell lysate
(1 mg/mL in 100 µl HBS-EP) and streptavidin beads coated with 1 µg /ml of OPB1 were used to pull down orexin A using the same PPD procedure and Western Blot protocol as described above with the exception that BSA was removed from the final wash buffer (Supplementary Fig. 3 ). 
Computational Modeling
Due to the higher binding affinity of OABP1, this peptide sequence was used for all computation modeling and sensor platform studies detailed in the remaining sections of this paper. The molecular modeling approach of characterizing the orexin A neuropeptide and binding peptide (OA-OABP1) interactions has two objectives. The first is to predict the three-dimensional arrangement of an OA-OABP1 complex given the known orexin-A three-dimensional structures 22 . The second objective is to estimate the OA-OABP1 binding energy. One of the most difficult problems in peptide-peptide docking is the flexibility of peptides which have many more degrees of freedom comparing with typical small molecules. To address this issue, a two-step process is typically used for predicting the structure of protein-protein complexes 23 . Initially, the proteins are considered as rigid molecules and a global search of the rotational and translational space is performed to generate a set of possible complexes. The second stage, called refinement, optimizes and rescores the generated rigid-body conformations by allowing small backbone and side-chain movements for both proteins 24 . We applied a similar approach to study the binding of peptides to the orexin A molecule. The rigid docking was performed by using the PatchDock package which is based on the molecular shape complementarity algorithm 25 . The generated structures were processed with the FireDock package for flexible docking 26 . FireDock performs refinement of each candidate complex by allowing side-chain flexibility and adjustment of the relative orientation of the molecules. The experimental NMR structure of the orexin A molecule was retrieved from the Protein Data Bank (code 1WSO). Coordinates from the first NMR structure were used in computational docking. Figure 2a shows the unbound structure of orexin A. The residues drawn in red (Leu16, Leu19, Leu20, His26, Gly29, Ile30, Leu31, Thr32 and Leu33) correspond to residues which are involved in binding to orexin-1 receptor 27 . It was shown by Darker et al. 27 that replacement of these residues with alanine resulted in a significant drop in functional potency at the Ox1R receptor. 
b) Ten representative unbound conformations for orexin A binding peptide (only backbone atoms are shown). Structures were visualized with Accelrys's Discovery Studio Visualizer (http://accelrys.com/products/discovery-studio/).
Short peptides, such as OABP1 and a negative control binding peptide (NCP) used in this study, are very flexible and often lack a well-defined conformation in their unbound state. Therefore, we generated an ensemble of unbound configurations for OABP1 and NCP using replica exchange molecular dynamics 28 . A total of 1000 generated conformations for each peptide were used in docking calculations. The representative ten unbound conformations for OABP1 are presented in Figure 2b (only backbone atoms are shown). The backbone atom root-mean square deviations were in the range of 1-5Å, which indicates a significant variability in peptide conformations. The docking of binding peptides to orexin A was performed in two steps. Initially, the PatchDock package, that considers molecules as rigid, was used to perform a global search of the rotational and translational space based on shape complementary to the generated set of possible complexes. The generated structures were refined using the FireDock software for each candidate complex by allowing the side chains flexibility and adjustments of the relative orientation of the molecules. The refined complexes were scored and ranked according to FireDock energy function. Figure 3 shows the highest ranked conformation of the OA-OABP1 complex. It can be easily seen that OABP1
peptide binds into the same region of the orexin A molecule as the Ox1R receptor through a combination of electrostatics, hydrogen bonding, and Van der Waals interactions. In the proposed structure of the complex, residue Leu12 is located at the side of orexin A molecule that allows it to link to the FET surface without the interruption of a complex.
NCP also binds to the orexin A molecule although at a much lower level compared with the OAPB1 (Table 2 ). Therefore, we refined the top predicted complex of orexin A with OABP1 using molecular dynamics (MD) simulations. We used the Amber10 29 package to perform MD simulations and the absolute binding free energy was calculated using the molecular mechanics/Poisson-Boltzmann surface area (MM/PBSA) methodology 30 :
To prepare a system for MM/PBSA calculations, the OA-OABP1 complex was solvated in a rectangular box of TIP3P water molecules. The system was initially minimized to 1000 steps followed by 35 ps of equilibration at 300K
with the restrain on all solute molecules. Next, we performed energy minimization for the entire system. Then, the system was equilibrated for 50 ps at 300K and, finally, we run a production run for 1 ns. The snapshots of the system trajectory were saved every 10 ps of MD simulations. These snapshots were used to extract the structure of the OA-OABP1 complex as well as unbound molecules. The entropic contribution was calculated using a normal-mode analysis 31 . 
Sensor Development and Testing
The electronic sensor platform is based on a zinc oxide field effect transistor (ZnO-FET), which has several device and biosensor advantages. First, ZnO is deposited via pulsed laser deposition at room temperature conditions which lends to less expensive fabrication demands and ability to use a variety of substrates, including flexible and lightweight plastics 32 . Secondly, ZnO deposited under the correct conditions naturally forms a vertically aligned nanostructure giving the semiconductor enhanced surface area which is ideal for FET sensors. High performance ZnO FETs have been developed for high speed electronic applications 33 and also used as a sensor platform for small molecule liquid state sensing using a DNA aptamer as a BRE 34 . The selectivity of the system reported here is based on a bi-functional peptide designed to bind to both the ZnO array. This is shown in Figure 4b where the surface morphology of the SiO 2 region is completely flat (Fig. 4a-ii) , whereas the ZnO region shows a large surface morphology change ( Fig. 4a-iii) due to the attachment of the bifunctional peptide to the semiconductor. The functionalized ZnO PeptiFET maintains a high performance after processing with ON/OFF ratios of 10 8 and good current response with modulation of both the gate (V G ) and source/drain (V SD ) voltages (Fig. 4c) . at a constant V G and V SD . For liquid state sensing, the PeptiFET must be rehydrated in order for effective binding of orexin A to take place. This is done by exposing the device to 20µL of water and monitoring the I SD until it is stabilized. At this time, the sensor can be exposed to solutions containing the target or negative control molecules. The sensor was exposed to a solution containing 10 nM orexin A for 1 min and the source drain current was monitored. A rapid response in the current was observed that reaches a Distribution A: Approved for public release; distribution unlimited.
88ABW-2012-2072, cleared 6 April 2012 plateau within 60 seconds. Orexin A has an overall positive charge (pI = 7.8), so the addition of a more positive charge distribution on the surface of the n-type semiconductor causes an increase in current upon binding. The sensor was exposed to varying concentrations of orexin A, (10 nM to 1 µM), and monitored over several minutes.
Exposure of the sensor to increasing concentrations of orexin A also resulted in a concomitant increase in current (Fig. 5a) . The magnitude of current increase at higher concentrations begins to decrease due to saturation of the peptide binding sites. for the given volume added corresponds to ~1200 total molecules of orexin A (Fig. 5b inset).
Real-time detection in biological fluids
The response of the PeptiFET to orexin A in water is an important study for the proof of concept of the device scheme, but the ultimate application of this sensor is in the real-time detection in biological fluids such as saliva and serum, where sub-nM detection is . Orexin A has a relatively low molecular weight (3561 g/mol) compared to many of the other molecules in the blood and saliva, such as blood cells, proteins, and enzymes. Therefore, a simple pre-processing step of size exclusion filtration using a 0.2 µm filter can be applied to both saliva and serum to lower the background noise of the biological fluid systems and increase the sensitivity on the PeptiFET. HPLC analysis of the biofluids before and after filtration show that the chemical composition of the samples were not altered (Supplemental Fig. 5 ). Before the filtration process, the sensitivity of the PeptiFET in a saliva matrix was seen at 1.4 µM (Supplemental Fig. 6 ). After filtration, the PeptiFET showed significant response to 10 fM (1x10 -14 ) of orexin A when spiked into a 20 µL drop of human saliva, as shown in Figure 5c . Likewise, the PeptiFET can detect down to 1 nM of orexin A when spiked in filtered fetal bovine serum (Fig. 5d) . A rapid initial increase in the current is observed in the presence of orexin A followed by a stabilization period. The rapid increase is likely due to the initial disruption of charged species near the semiconductor surface after dropwise addition of the target solution. Negative control experiments are essential to FET sensor evaluation since many semiconductor materials can show current response to a wide variety of molecules and environments. Orexin A tested on an unfunctionalized ZnO FET showed a negligible current change (Supplemental Fig. 7) . Thus the effects of non-specific binding of the target to the FET are minimal. The BREs add specificity to the sensor, but must also be evaluated against negative control target molecules. Since orexin A is a 33 amino acid peptide, the most stringent negative control that can be tested is a peptide with the same The randomized sequence is labeled as the negative control target (NCT). This molecule was exposed to the PeptiFET sensor at a concentration of 100 nM, where a slight increase in current (2x10 -7 A) was detected (Fig. 6a) . The same negative control peptide (NCP) used in binding kinetics and modeling (Table 1 ) was also used in the evaluation of the sensor performance.
The following sequence was used:
QRQLNDKLSIIS-GGGG-Z1 (NCP-Z1), where Z1 is the ZnO binding sequence, compared to the positive control: DQSNKIISLQRL-GGGG-Z1 (OABP1-Z1). In this case, 100 nM orexin A was exposed to a ZnO FET which was functionalized with NCP, again only a slight increase in current (2x10 -8 A) was observed (Fig. 6b) . However, when the negative control responses are overlaid with positive control responses (Fig. 6c) , they become negligible. Direct comparison of 100 nM exposures shows an increase in signal of 115X over the negative control target, and 1,115X over the negative control binding peptide. Additionally, the response of the positive control PeptiFET to 100 aM orexin A is also overlaid in Figure 6c , also showing the minimization of negative control response in water. Similarly, minimal response was seen in negative control testing in saliva (Supplemental Fig. 8 ). The data obtained in the PeptiFET with the OABP1-Z1 (Fig. 6b and 6c) showed a ~1000x increase in signal over the PeptiFET functionalized with the NCP, corresponding with the ~1000x increase in K D shown in Table 2 . 
DISCUSSION
Biomarker analysis in biofluids is a powerful tool for understanding the relationship between different types of events and the physiological and emotional state of a subject.
Current methods to study biomarker levels involve timed intervals of biofluid sampling during a tasking, offline analysis, and data correlation after the fact. Studies are limited due to the inability to include rapid biofeedback in order to modify the tasks in situ or to provide any augmentation to counter the detrimental events. One example of a proposed augmentation is the intranasal administration of orexin A 6 when decreases in attentional performance are observed indicated by lower orexin A levels in the subject.
Thus, we have developed a sensor platform approach to provide rapid biomarker analysis in biofluids. Through these final simulations, the binding energy of the top scoring complexes was determined at levels of low pM to nM range, corresponding well to the sensor data.
Additionally, the negative control binding peptide was analyzed the same manner, and showed a significant decrease in binding affinity of 1000X to high µM range, again correlating well to experimental values, where ~1000X greater signal was seen in positive control sensors over negative control.
This binding peptide was integrated into a field effect transistor (FET) structure where the binding of the target was transduced into an electrical signal. The advantages to this electrical based approach is (relative) ease of fabrication, ability of FETs to be highly arrayed, low power requirements (coin cell battery), and simple reporting that is amenable to wireless communication. This sensor architecture resulted in selective detection down to 100 aM concentrations in water (Fig. 5b) , 10 fM in filtered human saliva Distribution A: Approved for public release; distribution unlimited. 88ABW-2012-2072, cleared 6 April 2012 (Fig. 5c) , and 1 nM in filtered fetal bovine serum (Fig. 5d) . We have demonstrated the sensitivity and selectivity of the BRE by testing the sensor performance in complex fluids and using a variety of peptide controls.
We believe the sensor platform presented in this study can be used for analysis of a complex signature of biomarkers in multiple biofluids in real-time by arraying the FET elements and functionalizing each with a BRE specific to each biomarker, and applicable to a wide variety of neuroscience research applications.
MATERIALS AND METHODS
Peptides were custom synthesized and purchased from GenScript (New Jersey) and purified via HPLC to >95% purity with the following sequences: The bound phage were then eluted using 150 µl 200 mM glycine pH 2.2 (Aldrich) containing 0.5% BSA (Sigma) , rocked gently for 10 min at room temperature and neutralized using 15 µl of 1M Tris (Sigma) pH 9.1. The eluate was added to 20 mL E. coli ER2738 culture and incubated at 37 ºC with vigorous shaking for 4.5 h. The culture was transferred to a centrifuge tube and spun for 10 min at 10,000 x g at 40 ºC. The supernatant was collected and 1/6 volume of PEG/NaCl (20% PEG8000, 2.5 M NaCl) was added. The phage was allowed to precipitate at 40 ºC overnight. PEG precipitation was spun for 15 min at 10,000 g at 40 ºC. The pellet was re-suspended in 1 mL TBS, and re-precipitated with PEG/NaCl. Finally the pellet was suspended in 200 µL TBS, and stored at 40 ºC. The procedure was repeated 4 times for a total of 5 rounds of panning with the exception that the Tween concentration was increased 0.05% per round. Phage titers were determined as described in the Ph.D.-12 manual.
After five rounds of panning, 50 phage plaques were randomly selected from fresh titer plates using a sterile inoculation loops, and were amplified individually for 4.5-5 hours at 37 ºC in 1.5 mL of E. coli ER2738 culture grown in LB broth with 20 mg/L tetracycline (Sigma) until O.D. 600 = 0.4-0.6. After incubation, the amplified plaque solutions were centrifuged twice (6,000 rpm, 10 min) and the supernatants were transferred to a sterile 1.5 mL microcentrifuge tubes. Phagemid DNA was then isolated from the purified phage stocks using the Qiagen QIAprep Spin M13 kit (Qiagen). DNA concentration and purity measurements were made using a Thermo Fisher Scientific NanoDrop with the plate for 1 h at 37 °C. The solution was removed, and the plate was washed three times with PBS-tween. Horseradish peroxidase conjugated streptavidin was diluted 1:1000 in 0.1% BSA in PBS-tween, and 50 μL was added to each well and incubated for 1 h at 37 °C. The strepavidin solution was removed, and the plate was washed three times with buffer PBS-tween. Fifty μL of TMB (3,3′,5,5′-tetramethylbenzidine) was added to each well, and the solution was incubated for 15 min at 24 °C. Fifty μL of aliquot of 0.5 M HCl was added to stop the reaction, and the plate was scanned immediately using a SpectroMax plate reader. These assays were conducted in triplicate, and the data were then normalized by subtracting all fluorescent values from the no protein control, plotted, and fit using GraphPad Prism.
Sensor Platform: Equipment
Sensor device testing was done using a Keithley semiconductor parameter analyzer (SCS 4200) and MMR 4-probe station for addressing the FET source and drain electrodes. Atomic force microscopy images were taken with a Veeco BioScope AFM in tapping mode.
Functionalization
A 3" silicon wafer with a dense array of ZnO FETs was diced into ~15 mm x 5 mm FET arrays. These smaller arrays contain 6 FETs with identical geometries (Fig. 4a) which can each be tested individually. The bifunctional peptides were solubilized in UltraPure water at a concentration of 20 µg/mL and aliquotted into 1.5 mL sterile (autoclaved) plastic vials at a volume of 1 mL. The diced FET arrays were then incubated in the vial, gently shaken for 6 minutes, and immediately washed with UltraPure water and dried with nitrogen. Both the peptide concentration and incubation times were optimized for this sensor system. The peptide functionalized ZnO FET (PeptiFET) was then evaluated for sensor performance (preferably within 4 hours of functionalization). 
Device Testing
The PeptiFET devices were tested in a real-time mode by applying a constant source/drain voltage (V SD ) and gate voltage (V G ) and monitoring the source/drain current (I SD ) at a rate of one data point per second. In order for effective target binding to take place, the binding peptide must be rehydrated. This was done by applying an initial 20 µL drop of UltraPure water and monitoring the current (I SD ) until stabilized (~2-3 minutes).
When I SD reached a stable value, the target solutions were applied and sensor performance analyzed.
Modeling
In our computational study, we used the 3D structure of orexin A determined using a two-dimensional nuclear magnetic resonance (NMR) spectroscopy and posted into the Protein Data Bank (PDB code 1WSO) 22 . The structures of OABP1 were generated using the Rosetta ab initio fragment assembly package 38 . The 1000 top-scoring structural models were refined by energy minimization, rescored with an implicit solvent model, and clustered by a pairwise hierarchical method to identify a set of unique structures using a protein structure prediction pipeline (PSPP) 39 . To account for the peptide flexibility, an ensemble docking technique was applied. The models with the lowest energy in ten clusters as predicted by PSPP were selected as input structures for replica exchange molecular dynamics (REMD) simulations 40 .
The REMD simulations were performed with the Amber10 29 suite of programs as implemented in Automatic Protein Ensemble Generator (https://applications.bioanalysis.org/apeg). Eight replicas distributed over a temperature range from 270 to 600 K were used. The implicit water simulations for each replica were initially equilibrated for 200 ps at the corresponding temperature following by 5 ns of production run. The time step was set to 2 fs and SHAKE was applied to constrain the bonds connecting hydrogen atoms. The temperature exchanges were attempted every 1 ps and 5000 snapshots from the production run were used for cluster analysis.
Clustering was performed with the Amber10 PTRAJ modules based on the pairwise backbone-atom only root-mean square deviations (RMSD). 
